Bibliografia

  1. Beutner KR, Tyring S. Human Papillomaviruses and human disease. Amer J Med 1997;102:9-15.
  2. Gloria YF, Bierman R, Beardsley L, et al. Natural history of cervico-vaginal papillomavirus infection in young women. New England J Med 1998; 338:423-428.
  3. Koutsky L. Epidemiology of genital human papillomaviruses infection. Amer J Med. 1997; 102: 3-8.
  4. Kreider JW, Howertt MK, Stoler MH, Zaino RJ, Welsh P. Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11. Int J Cancer. 1987;39:459-465.
  5. Walboomers JM, Meijer CJ. Do HPV negative cervical carcinoma exist ? J. 1997;181: 253-254.
  6. Beutner KR, Ferenczy A. Therapeutic approaches to genital Warts. Amer J Med 1997; 102:28-37.
  7. Jacobs S; Grussendorf EI, Rosener I, Rubben, A. Molecular analisis of the effect of topical imiquimod treatment of HPV 2/27/57 induced common warts. Skin Pharmacol Physiol 2004; 17: 258-266.
  8. Luger T. Treatment of immune mediated skin diseases: Future perspectives. Eur J Dermatol 2001;11: 343-347.
  9. Bernstein DI, Harrison CJ, Tepe ER, Shahwan A, Miller RL. Effect of imiquimod as an adjuvant tor immunotherapy of genital HSV in guinea-pigs. Vaccine 1995; 13:72-76.
  10. Krebs HB. The use of topical 5-Fluoracil in the treatment of genital condilómas. Obst. Gynecol Clin North Am 1987;14:559-564.
  11. Lobe DC, Kreider JW, Phelps WC. Therapeutic evaluation of compounds in the SCID-RA papillomavirus model. Antiviral Res 1998;40:57-71
  12. Bernard HU. Established and potencial strategies against papilomavirus infections. J Antimicrob Chemother 2004; 53:137-139.
  13. Nelson L. The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts. Int J STD AIDS 2002;13:29-35.
  14. Gibbs S, Harvey I, Sterling JC, Stark R. Local treatments for cutaneous warts. Cochrane Database Syst Rev. 2003; 43: 28-39.
  15. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004; 70:2335-2342.
  16. Senatori R, Dionisi B, Lippa P, Inghirami P. Utilizzo dell•imiquimod nel trattamento della condilomatosi ano-genitale. Nostra esperienza. Minerva Ginecol 2003;55:541-546
  17. Ries RK, Jaffe C, Comtois KA, Kaichell M. Treatment satisfaction compared with outcome in severe dual disorders. Comm. Ment Health J 1999;35: 213-221.
  18. Kaspari M, Gutzmer R, Kiehl P, Dumke P. Kapp A, Brodersen JP. Imiquimod cream in the treatment of human papillomavirus 16 positive erytroplasia of Queyrat. Dermatology. 2002; 205: 67-69.
  19. Gibbs S, Harvey L, Sterling J, Stark R. Local treatment for cutaneus warts systematic rewiew. BMJ 2002; 325:461-463.
  20. Gross G. Humane Papillomaviren. Ther Umsch 2003; 60:595-604.
  21. Feldman SR, Fleischer AB, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999 40: 43-47.
  22. Iscimen A, Aydemir EH, Goksugur N, Engin, B. Intralesional 5fluorouracil lidocaine and epinephrine mixture for the treatment of verrucae a prosprective placebo-controlled single blind randomized study. J Eur Acad Dermatol Venereol 2004 ;18:455-458.
  23. Halasz CL. Treatment of warts with topical pyruvic acid : with and without added 5-fluorouracil. Cutis 1998; 62:283-285.
  24. Speck NM, Ribalta J C. Focchi J, Costa RR, Kesselring F, Freitas VG. Low-dose 5-fluorouracil adjuvant in laser therapy for HPV lesions in immunosuppressed patients and cases of difficult control. Eur J Gynaecol Oncol 2004; 25; 597-599.